List of quality statements
Statement 1. Adults who are having transurethral resection of bladder tumour (TURBT) have detrusor muscle obtained during the procedure.
Statement 2. Adults with suspected bladder cancer are offered a single dose of intravesical mitomycin C, given at the same time as the first transurethral resection of bladder tumour (TURBT).
Statement 3. Adults with bladder cancer have access to a designated clinical nurse specialist.
Statement 4. Adults with newly diagnosed non‑muscle‑invasive bladder cancer have a risk classification of their cancer completed.
Statement 5. Adults with high‑risk non‑muscle‑invasive bladder cancer discuss intravesical Bacille Calmette‑Guérin (BCG) and radical cystectomy with a urologist who performs both treatments and a clinical nurse specialist.
Statement 6. Adults with muscle‑invasive urothelial bladder cancer discuss neoadjuvant chemotherapy, radical cystectomy and radiotherapy using a radiosensitiser with a urologist who performs radical cystectomy, a clinical oncologist and a clinical nurse specialist.
Statement 7. Adults who have had low‑risk non‑muscle‑invasive bladder cancer and who have no recurrence of the bladder cancer within 12 months of their initial transurethral resection of bladder tumour (TURBT) are discharged to primary care.